Enterologics Inc. (fka ELGO)

[Renee]

ELGO revoked:

http://www.sec.gov/litigation/admin/2015/34-75799.pdf

[Renee]

ELGO SEC Suspension for Financials delinquencies:

http://www.sec.gov/litigation/suspensions/2015/34-75184.pdf

Order:

http://www.sec.gov/litigation/suspensions/2015/34-75184-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2015/34-75185.pdf

[king koopa]

beautiful close .02 x .05!!!

[king koopa]

been bidding for some of this since July, finally filled me some shares 50K @ .015. Looks like one of those buy and hold stocks that randomly goes insane one day eventually

[jeffn]

sounds good. on watch. needs more volume.

[Big_Money_Upward]

TBX??? More movement friday. Shares Outstanding 37,163,391 a/o Nov 12, 2012 subtract Total # of shares held by insiders 17,338,500
=19,824,891 shares....=just under 20mill....
So its under .05 and has a tight float that appears to be just under 20mil.

[jwez]

Drop...

[Hedge Starz]

what did it say? i just marked this one

[Hedge Starz]

explain? what is up over here. checking this one out now.

[$King]

ELGO is buying BBAL shares $!$

[$King]

ELGO now owns BBAL

[anivad21]

Enterologics Is Acquiring BioBalance Corp. and Probiotic Product from New York Health Care, Inc.

Enterologics Will Establish Clinical Development Program for E. coli M17 (Probactrix(R))

SAINT PAUL, Minn., Jun 17, 2011 (BUSINESS WIRE) -- Enterologics, Inc. (ELGO.OB) announced today that it is acquiring all the shares of The BioBalance Corporation and its subsidiary BioBalance LLC from New York Health Care, Inc. ("NYHC"). With this purchase Enterologics will acquire E. coli M17, or Probactrix(R), a probiotic product being developed as a biologic drug under an active Investigational New Drug (IND) application for a pouchitis-related indication. Probiotics are live microorganisms (in most cases, bacteria) that are similar to or derived from beneficial microorganisms found in the human gut. They are also called "friendly bacteria" or "good bacteria."
The acquisition also includes BioBalance's portfolio of intellectual property and regulatory filings. Terms of the acquisition include cash, stock and a 3-year promissory note. The sale is contingent upon receiving approval by NYHC's shareholders, with an expected closing date of no later than September 30, 2011.

"By providing us with our first pipeline product, E. coli M17, the acquisition of BioBalance fulfills a key milestone in Enterologics' business strategy," said Bob Hoerr, Enterologics' president. "E. coli M17 coupled with the new formulation technology we are developing with Universal Stabilization Technologies provides us with a solid platform for our first probiotic biologic drug product. The fact that BioBalance was able to establish an active IND for E. coli M17 made it very attractive for acquisition. This further demonstrates the validity of our planned commercialization of high value probiotics as biologic drugs for specific gastrointestinal (GI) conditions."

Dr. Hoerr stated that the formal development of E. coli M17 could begin quickly once the deal closes. He continued that the Company plans to reinitiate manufacturing with a partner as soon as feasible after closing. When cGMP production and the necessary financing are in place, the Company intends to begin clinical trials under the IND.

"The sale of BioBalance will enable New York Health Care to concentrate on its core business," said Murry Englard, CEO of NYHC. "We are also very pleased that Enterologics is committed to developing E. coli M17 as a therapeutic agent. We made significant progress on this course until the economic downturn made obtaining the required financing impossible. As a focused GI therapeutic company, Enterologics is ideally suited to be successful."

About Enterologics

Enterologics, Inc. (OTCBB: ELGO.OB) is a biotechnology company that is developing probiotics as biologic drugs for specific gastrointestinal disease indications. Probiotics are live microorganisms, in most cases, bacteria, that are similar to or derived from beneficial microorganisms that are found in the human gut (e.g. for more information see Introduction to Probiotics). They are also called "friendly bacteria" or "good bacteria." Enterologics intends to identify, in-license and develop unique probiotic strains for specific medical conditions, obtain regulatory approval and market these probiotics products as FDA-approved prescription drugs for specific label indications. More details are available at http://www.enterologics.com.

Forward-Looking Statements

The U.S. Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation.

Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The forward-looking statements in this release are based upon various assumptions. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that it will achieve or accomplish these expectations, beliefs or projections. Actual results could differ materially from those discussed in the forward-looking statements. Reference is made to our filings with the SEC.

KEYWORDS: Probiotics, Biologics, Biotechnology, Gastrointestinal Diseases

SOURCE: Enterologics, Inc.

CONTACT:
Enterologics, Inc. Beth Seidman, 516-303-8181 [e-mail] http://www.enterologics.com
Copyright Business Wire 2011
-0-
KEYWORD: United States
North America
Massachusetts
Minnesota
INDUSTRY KEYWORD: Health
Biotechnology
Infectious Diseases
Pharmaceutical
Other Health
General Health
SUBJECT CODE: Merger/Acquisition

[stockseekerok]

ELGO has been waking up Has News out

[anivad21]

From: Yitz Grossman
Thursday, June 2, 2011 1:40 PM

Thank you for your mail and interest in Enterologics. And of course, we welcome you as a shareholder. Might we ask that you follow recent news releases and one planned for next week. I believe next week’s release will clarify some of you questions. If not, kindly reach out to us again and I’ll call you with better answers.


Just wanted everyone to know things are coming this week.

[anivad21]

Not a lot going on with this board right now. Seems like a great company with a real future. If they do what they are saying this will be big. I work in the health field and GI issues are big problems for children and aging adults. Which is where most of our population is right now. People over 65 and those under 18...Will be great to see this one grow, and I don't see why it will not. I am in for the long haul. If my order will ever fill. I am upping my bid tomorrow and hope to get in with all of you for this great ride!

[anivad21]

super pissed I have been trying to buy at .36 for two hours! Why is the last order .34

[wizard sleeve]

It is down because

People took their profits when I ran up after being touted by penny finder sites.

The better question is if the after hours trading is correct. I show it up 36% on Ihub and Etrade. If that is true we might be able to grab up some more profit tomorrow.

[trader0725]

why elgo is down 30% today.....

[yaboy520]

I Got An Alert In My Email Today On This Stock

[bigtuna177]

ELGO - Nice day trading today!!!

[pinkslipjunkie]

ELGO Not a bad day of trading and continous volume.

[bigtuna177]

ELGO - YESS... Grean is green no maater how high it is!!! Solid trading range today for sure and just sets up the accumulation for another day! NP by me! GL....

[zigzagman]

$ELGO ~ CLOSED UP 2.08% ~ UP $.01 ~ VOLUME OF 81,794

[bigtuna177]

ELGO - Well we gots our green close!!! WEEEEEEEEEEEEEEEEEE

[bigtuna177]

ELGO yup and thanks! the 52 week High/Lo range is failry tight 36-60 and the 60 was just hit a few last Monday so we could easily get back there. Not a HUGE swing and not really any resistance that I see. IMO

[zigzagman]

$ELGO - Daily Candlesticks:

Holding up VERY well...IMO

[bigtuna177]

ELGO exactly! That 49-50 nut is a tough one to crack! At elast we aren't messing with a dime!!! LOL

[stockforyou1]

ELGO is still moving right along.

[bigtuna177]

ELGO and ASCM still sitting tight on the ask but 49 holding strong. Great sign IMO!!! GL

[Pastor Phil]

that 50 cent piece is a challenge

[Carlito]

ELGO >> going for a green close !)

[bigtuna177]

ELGO - Volume slowly creeping up and holding those 49's. They are not thick here, hop;ing for a solid 50 on the close. GL

[bigtuna177]

ELGO - Nice email! I hope that went out to a lot of folks! This is good stuff and at worse case, we are in a tad before the rush, I just don't see this staying this low. IMO of course! GL...

[Carlito]

ELGO .49 >> vol. 73k >> good to know more groups <OO> it !!

[Quik18holes]

ELGO was founded in 2009 for the sole purpose of making probiotics available as new therapeutic alternatives for inadequately treated GI diseases. We operate as a virtual team of experts and partner with the best outside biologic production resources we can identify. Our goal is to keep development costs low and make time to market as fast as possible.

Our mission is to bring unique strains of probiotic bacteria to market as FDA-approved “live biotherapeutics” for gastrointestinal diseases.

http://www.enterologics.com/company.html

Recent Headlines

[Carlito]

ELGO


who = mm ASCM

ASCM P ASCENDIANT CAPITAL MARKETS, LLC

http://www.ascendiant.com/upload/Ascendiant%20E-Brochure.pdf
They are more than just another MM.

[bigtuna177]

YUP...A chruning we wil go! 49 is now thin and really would hope to see this push into the 50's.

[Carlito]

ELGO .49 lets smack'' mm ascm ''off the ask !

[Quik18holes]

Gotta like that?! More .49 hits, HOD test coming IMO

ELGO

[Quik18holes]

ELGO MGMT. & Board ..

Robert Hoerr, M.D., PhD. President, Director and Co-Founder.
From October 2004 through October 2009, Dr. Hoerr was Chairman, Chief Executive Officer and a director of Nanocopoeia, Inc., a development stage drug-delivery company that he co-founded. He continues to serve as a director and to provide research and development guidance for Nanocopoeia. From October 2004 to the present, he has been the president and owner of Nutramentals, Inc., a medical and regulatory consulting firm specializing in pharmaceutical and biologic development, as well as strategic planning for developmentstage companies. Dr. Hoerr is board-certified in Internal Medicine. He obtained his M.D. from Indiana University School of Medicine and his Ph.D. in Nutritional Biochemistry from M.I.T.

Lawrence Levitan, M.D. Treasure, Director and Co-Founder.
Dr. Levitan is board-certified in obstetrics and gynecology and is affiliated with Beth Israel Medical Center, New York, where he has maintained an active practice since January 1999. Dr. Levitan's medical background facilitates his ability to contribute to medical and technical issues encountered by the Company.

William Welwart. Vice President, Director and Co-Founder.
Mr. Welwart has been a pharmaceutical consultant to the pharmaceutical industry since 2007. Prior to that, he was Director of Operations for 15W Pharmacy Edison, Inc. Mr. Welwart brings broad experience and skills in the pharmaceutical industry and its channels of distribution.

http://www.enterologics.com/company.html

[bigtuna177]

ELGO - Exactly why this is one company you can really like in the long run. Solid building of a product that is needed. Nice, very nice.

[stockforyou1]

New Trade Suggestion

Enterologics Inc (OTCBB: ELGO)
• Alert Price: 0.48
• Sell Point: when you are comfortable with the gains

Technical Indicators
ELGO has just recently begun trading on the stock market, which is why I believe the technicals could be significantly undervalued at the moment because the investment community, simply put, has not yet noticed this company. "New Issues" as they are called, are always interesting plays and often create great opportunities for traders.

Several weeks ago, ELGO appreciated in value from 0.44 to 0.57 in just 2 days on extraordinary volume. Afterwards, as we can tell by looking at the chart, the valuation decreased back down to solid support levels at around 0.44.

In the past 2 days we have once again noticed an appreciation in market valuation on increasing volume. This is an extraordinary bullish indicator that shows us that there is support at each new trading level.

Moreover, ELGO has been closing the past few days at the high of the day. Remember, I told everyone that I needed to see how ELGO would close the day before I alert it. Well this is the reason. This is an ENORMOUS factor, in all regards.

With such factors, combined with an oversold RSI that is presently at 45 on the daily chart, we can see much more upside.

Another thing that I would like to note when it comes to the technical indicators is the fact that our next resistance point is at about 0.57 which gives ELGO almost 20% of EASY upward movement before we witness some consolidation.

[Carlito]

ELGO .49 << tight range today .48/.50 << accumulation !

[Quik18holes]

Enterologics is assembling a scientific advisory board of thought leaders in gastroenterology and microbiology. Members will be announced in the near future.

The scientific advisory board will help us to identify and select candidate probiotic strains for clinical development. Because probiotic bacteria have unique characteristics and potential mechanisms of action in the body, the board will also help match those qualities with particular disease conditions that are inadequately addressed by current therapies.

http://www.enterologics.com/company.html

Recent Headlines

Company info: http://www.otcmarkets.com/stock/ELGO/quote;

ELGO

[stockforyou1]

ELGO back to $0.49

[Quik18holes]

Sure does! ..looks like seller is slowing here as Bulls rock the Ask?! IMO

ELGO .48 X .49 >> Vol 69.8K~

Company info: http://www.otcmarkets.com/stock/ELGO/quote;
Website: http://www.enterologics.com

[stockforyou1]

ELGO $0.48 x $0.49 - churning

[zigzagman]

$ELGO ~ Time & Sales for today:

[moneymaker168]

Yes yes, blue sky soon. ELGO is getting some nice size buys here on the ask. $0.50 may fall soon. $0.55 is up next.

[moneymaker168]

To learn about Probiotics

Probiotics: Medical Interest
New interest. Fresh interest in probiotics was prompted by reports in the popular press linking yogurt consumption with longevity. There were also grave concerns in the medical literature about a striking rise in antibiotic resistant bacteria as well as the destructive effects of antibiotics on the healthy gut flora. More recently, the presence of damaging bacteria residing in the gut (H. pylori) has been shown to be a primary cause of peptic ulcers, a disease that had previously been thought to be caused by too much acid or stress. Some scientists believe that infection with a yet-to-be microorganism may be an underlying factor leading to inflammatory bowel disease. These trends stimulated more research on strains of bacteria isolated from healthy gut flora as well as from the family of strains used to ferment foods and dairy products, resulting in the identification of a number of Lactobacillus, bifidobacteria, E. coli and yeast strains that had beneficial effects on human and animal health.

Growing clinical evidence. The medical literature has reported positive results of the probiotics to:
Prevent or treat antibiotic associated diarrhea, including that caused by Clostridium difficile
Treat diarrhea, such as rotavirus in children
Treat irritable bowel syndrome
Prevent or treat infections in the urinary tract or female genital tract (e.g. vagina)
Reduce recurrence of bladder cancer
Treat or prevent pouchitis, a condition that follows removal of the colon to treat ulcerative colitis
Treat or manage eczema, or atopic dermatitis, especially in children